MARTA ISABEL
SIERRA ZAPICO
Investigadora
Hospital Universitario Central de Asturias
Oviedo, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario Central de Asturias (13)
2020
-
Epigenetic downregulation of TET3 reduces genome-wide 5hmC levels and promotes glioblastoma tumorigenesis
International Journal of Cancer, Vol. 146, Núm. 2, pp. 373-387
-
Global hyperactivation of enhancers stabilizes human and mouse naive pluripotency through inhibition of CDK8/19 Mediator kinases
Nature Cell Biology, Vol. 22, Núm. 10, pp. 1223-1238
-
No genome-wide DNA methylation changes found associated with medium-term reduced graphene oxide exposure in human lung epithelial cells
Epigenetics, Vol. 15, Núm. 3, pp. 283-293
2019
-
Chromatin regulation by Histone H4 acetylation at Lysine 16 during cell death and differentiation in the myeloid compartment
Nucleic Acids Research, Vol. 47, Núm. 10, pp. 5016-5037
-
Epigenetic Deregulation of Protocadherin PCDHGC3 in Pheochromocytomas/Paragangliomas Associated With SDHB Mutations
The Journal of clinical endocrinology and metabolism, Vol. 104, Núm. 11, pp. 5673-5692
2018
-
Epigenetic dysregulation of TET2 in human glioblastoma
Oncotarget, Vol. 9, Núm. 40, pp. 25922-25934
-
SDHC promoter methylation, a novel pathogenic mechanism in parasympathetic paragangliomas
Journal of Clinical Endocrinology and Metabolism, Vol. 103, Núm. 1, pp. 295-305
2017
-
Cisplatin resistance in cell models evaluation of metallomic and biological predictive biomarkers to address early therapy failure
Metallomics, Vol. 9, Núm. 5, pp. 564-574
2016
-
The effect of exposure to nanoparticles and nanomaterials on the mammalian epigenome
International Journal of Nanomedicine, Vol. 11, pp. 6297-6306
2013
-
Long-term biomonitoring of breast cancer patients under adjuvant chemotherapy: the comet assay as a possible predictiv
Mutagenesis, Vol. 28, Núm. 1, pp. 39-48
2011
-
Pegylated liposomal doxorubicin and gemcitabine in a fixed dose rate infusion for the treatment of patients with poor prognosis of recurrent ovarian cancer: A phase Ib study
International Journal of Gynecological Cancer, Vol. 21, Núm. 3, pp. 478-485
2007
-
Phase II study with the combination of gemcitabine and DTIC in patients with advanced soft tissue sarcomas
Cancer Chemotherapy and Pharmacology, Vol. 59, Núm. 2, pp. 251-259